We are live on ! Find out more
AUPH icon

Aurinia Pharmaceuticals

14.70 USD
-0.19
1.28%
At close Updated Nov 20, 4:00 PM EST
Pre-market
After hours
14.64
-0.06
0.41%
1 day
-1.28%
5 days
-6.55%
1 month
-12.19%
3 months
-14.88%
6 months
-7.55%
Year to date
-4.23%
1 year
-2.91%
5 years
-25.19%
10 years
320%
 

About: Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.

Employees: 128

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 60%
Neutral 20%
Negative 20%
Positive
Zacks Investment Research
21 days ago
Aurinia Pharmaceuticals (AUPH) Tops Q3 Earnings Estimates
Aurinia Pharmaceuticals (AUPH) came out with quarterly earnings of $0.23 per share, beating the Zacks Consensus Estimate of $0.2 per share. This compares to earnings of $0.23 per share a year ago.
Aurinia Pharmaceuticals (AUPH) Tops Q3 Earnings Estimates
Neutral
Business Wire
21 days ago
Aurinia Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended September 30, 2026 and Provides Update on Recent Business Progress
EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced financial results for the three and nine months ended September 30, 2026 and provided an update on recent business progress. Financial Results Total Revenue: For the three and nine months ended September 30, 2026, total revenue was $83.7 million and $244.6 million, up 14% and 19%, respectively, from $73.5 million and $205.9 million, respectively, in the same periods of 2025. Net Product Sales: For th.
Aurinia Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended September 30, 2026 and Provides Update on Recent Business Progress
Negative
Zacks Investment Research
24 days ago
Earnings Preview: Aurinia Pharmaceuticals (AUPH) Q3 Earnings Expected to Decline
Aurinia (AUPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Aurinia Pharmaceuticals (AUPH) Q3 Earnings Expected to Decline
Positive
Zacks Investment Research
25 days ago
Why Aurinia Pharmaceuticals (AUPH) is a Top Growth Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why Aurinia Pharmaceuticals (AUPH) is a Top Growth Stock for the Long-Term
Positive
Zacks Investment Research
28 days ago
Why Aurinia Pharmaceuticals (AUPH) is a Top Momentum Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why Aurinia Pharmaceuticals (AUPH) is a Top Momentum Stock for the Long-Term
Positive
Zacks Investment Research
3 months ago
Aurinia Settles Voclosporin Patent Litigation With Teva, Stock Rises
AUPH settles voclosporin patent litigation with Teva, delaying potential generic competition in the United States until December 2036.
Aurinia Settles Voclosporin Patent Litigation With Teva, Stock Rises
Positive
Benzinga
3 months ago
Aurinia Pharmaceuticals and Teva Settle Patent Dispute for Kidney Disease Drug
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) shares are up during Thursday's premarket session as the company has entered into a settlement agreement with Teva Pharmaceutical Industries Ltd. (NYSE:TEVA).
Aurinia Pharmaceuticals and Teva Settle Patent Dispute for Kidney Disease Drug
Neutral
Business Wire
3 months ago
Aurinia Settles Patent Litigation with Teva
EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Settles Patent Litigation with Teva.
Aurinia Settles Patent Litigation with Teva
Neutral
Seeking Alpha
3 months ago
Aurinia Pharmaceuticals Doubles Down On Its Pipeline
Aurinia Pharmaceuticals is running the phase 4 PRESERVE trial in lupus nephritis, which tests combinations containing the company's drug Lupkynis. Lupkynis could face potential challenges to its market exclusivity in the not-too-distant future. AUPH is developing aritinercept in four potential indications but doesn't provide much clarity on timelines for further updates.
Aurinia Pharmaceuticals Doubles Down On Its Pipeline
Positive
Zacks Investment Research
3 months ago
Aurinia Pharmaceuticals (AUPH) Surpasses Q2 Earnings Estimates
Aurinia Pharmaceuticals (AUPH) came out with quarterly earnings of $0.28 per share, beating the Zacks Consensus Estimate of $0.19 per share. This compares to earnings of $0.16 per share a year ago.
Aurinia Pharmaceuticals (AUPH) Surpasses Q2 Earnings Estimates
Price charts implemented using Lightweight Charts™